ClinicalTrials.Veeva

Menu

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

National Taiwan University logo

National Taiwan University

Status

Unknown

Conditions

Pancreatic Cancer

Treatments

Device: The imaging biomarkers determined by MR-PET

Study type

Observational

Funder types

Other

Identifiers

NCT02550847
201407052MINC

Details and patient eligibility

About

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Full description

The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

Enrollment

100 estimated patients

Sex

All

Ages

20 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Diagnosed as pancreatic cancer
  2. Between 20~90 years old
  3. ECOG 0-2
  4. Normal renal function
  5. Measurable tumor size (>1cm)

Exclusion criteria

  1. Contraindication for MRI exam
  2. Claustrophobia
  3. Renal insufficiency
  4. Other malignancy
  5. Pregnancy and lactating women

Trial contacts and locations

1

Loading...

Central trial contact

Ting-Fang Shih, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems